UTHR Stock: Why 40% Margins and $3.3B Cash Point to 25% Upside

Deep value meets growth in this overlooked biotech with multiple near-term catalysts. United Therapeutics Corporation (UTHR: NASDAQ) is a biotechnology company that develops and commercializes therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). Trading at $304, UTHR stock appears significantly undervalued based on its strong balance sheet, exceptional profitability, and multiple near-term catalysts. This analysis looks at technical patterns, fundamental metrics, and valuation multiples to determine whether UTHR could reach my $380 price target within 6–12 months.